KXKun Xiao

Kun Xiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kun Xiao has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Chang Liu

    School of Medicine, Nankai university, Tianjin 300000, China; Center of Pulmonary & Critical Care Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing 100853, China

    4 shared publications
  • Binbin Li

    Scientific Research Center, the Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, China

    2 shared publications
  • Dunqing Li

    Health and Sport Administration, Muskingum University, Ohioan, USA

    2 shared publications
  • Ling Ma

    Department of Cardiology, the 940(th) Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou 730050, China

    2 shared publications
  • Lixin Xie

    Senior Department of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital

    2 shared publications
  • Qian Zhang

    Department of Geriatric Diseases, the Seventh Medical Center of Chinese PLA General Hospital, Beijing 100700, China

    2 shared publications

Latest Publications

  • Effects of traditional Chinese medicine on treatment outcomes in severe COVID-19 patients: a single-centre study

    by Yongjiu Xiao, Binbin Li, Chang Liu, Xiuyu Huang, Ling Ma, Zhirong Qian, Xiaopeng Zhang, Qian Zhang, Dunqing Li, Xiaoqing Cai, et al.


  • Open Access

    Progress in preclinical studies of macrophage autophagy in the regulation of ALI/ARDS

    by Chang Liu, Kun Xiao, Lixin Xie

    Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a critical clinical syndrome with high morbidity and mortality that poses a major challenge in critical care medicine. The development of ALI/ARDS involves excessive inflammatory response, and macrophage autophagy plays an important role in regulating the inflammatory response in ALI/ARDS. In this paper, we review the effects of autophagy in regulating macrophage function, discuss the roles of macrophage autophagy in ALI/ARDS, and highlight drugs and other interventions that can modulate macrophage autophagy in ALI/ARDS to improve the understanding of the mechanism of macrophage autophagy in ALI/ARDS and provide new ideas and further research directions for the treatment of ALI/ARDS.


  • Top Cited Papers
    Open Access

    Advances in the Regulation of Macrophage Polarization by Mesenchymal Stem Cells and Implications for ALI/ARDS Treatment

    by Chang Liu, Kun Xiao, Lixin Xie

    Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a common condition with high mortality. ALI/ARDS is caused by multiple etiologies, and the main clinical manifestations are progressive dyspnea and intractable hypoxemia. Currently, supportive therapy is the main ALI/ARDS treatment, and there remains a lack of targeted and effective therapeutic strategies. Macrophages are important components of innate immunity. M1 macrophages are pro-inflammatory, while M2 macrophages are anti-inflammatory and promote tissue repair. Mesenchymal stem cells (MSCs) are stem cells with broad application prospects in tissue regeneration due to their multi-directional differentiation potential along with their anti-inflammatory and paracrine properties. MSCs can regulate the balance of M1/M2 macrophage polarization to improve the prognosis of ALI/ARDS. In this paper, we review the mechanisms by which MSCs regulate macrophage polarization and the signaling pathways associated with polarization. This review is expected to provide new targets for the treatment of ALI/ARDS.


  • Open Access

    Effects of traditional Chinese medicine on treatment outcomes of severe COVID-19 patients: A single-centre study.

    by Kun Xiao, Yongjiu Xiao, Binbin Li, Chang Liu, Xiuyu Huang, Ling Ma, Zhi Rong Qian, Xiaopeng Zhang, Qian Zhang, Dunqing Li, et al.

    No specific effective therapeutic drugs have been identified for COVID-19. Critically ill COVID-19 36 patients in the ICU experience high mortality. This project aims to study the effects of traditional 37 Chinese medicine (TCM) treatment on deadly outcomes caused by COVID-19. A total of 123 critically 38 ill COVID-19 patients who received close monitoring at the ICU of Vulcan Hill Hospital between 39 ICU patients received supportive management. Eighty-one patients were given additional TCM 41 treatment. Clinical characteristics during the treatment period (up to 39 days) and the clinical outcome 42 of each patient were closely monitored and analysed. We observed that patients treated with TCM had 43 lower mortality than the non-TCM treatment group (16 of 81 vs. 31 of 42; 0.3 person/month vs. 2.9 44 person/month). In the adjusted Cox proportional hazards models, TCM treatment was associated with 45 improved survival [multivariate HR, 0.13; 95% confidence interval (CI), 0.06–0.24; P < 0.001]. 46 Furthermore, we found that TCM treatment could partially improve the inflammation status by 47 reducing the levels of proinflammatory cytokines and recovering multiple organic functions. TCM 48 treatment may decrease inflammation status by reducing the level of proinflammatory cytokines and 49 allowing the recovery of multiple organic functions, which could improve the survival rate of critically 50 ill COVID-19 patients.

  • Immunodeficiency in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

    by Sheling Xie, Kaifei Wang, Wei Zhang, Kun Xiao, Peng Yan, Yanqin Li, Wanxue He, Yuhan Zhang, Lixin Xie

    Chronic obstructive pulmonary disease (COPD), characterized by progressive airway inflammation and irreversible airflow limitation, leads to serious decline in life quality. The acute exacerbation of COPD (AECOPD) results in high healthcare costs as well as a significant mortality rate. The most common cause of acute exacerbation is infection. Immune deficiency, which induces dysfunction of anti-infection, plays an important role in the pathogenesis of acute exacerbation. As described in this review, the immune dysfunction in patients with AECOPD can be a major focus of efforts to therapeutic strategy.